Pipeline — registered trials by phase
A Natural History Study of Corneal Abrasions in Patients With Dystrophic Epidermolysis Bullosa (DEB)
— · Epidermolysis Bullosa Dystrophica, Epidermolysis Bullosa Dystrophica, Recessive, Epidermolysis Bullosa Dystrophica Dominans · Recruiting · est. 2025-12
Long-Term Follow-up Protocol
— · Dystrophic Epidermolysis Bullosa, Recessive Dystrophic Epidermolysis Bullosa, Dominant Dystrophic Epidermolysis Bullosa · Recruiting · est. 2028-05-25
A Study Assessing KB407 for the Treatment of Cystic Fibrosis
— · Cystic Fibrosis · Recruiting · est. 2026-12
A Study of KB408 for the Treatment of Alpha-1 Antitrypsin Deficiency
— · Alpha 1-Antitrypsin Deficiency · Recruiting · est. 2025-12
A Study to Investigate Safety and Efficacy of KB111 for the Treatment of Hailey-Hailey Disease
— · Hailey Hailey Disease, Skin Diseases, Lesion Skin · Recruiting · est. 2026-11
A Phase I Study of KB301, a Replication-Incompetent, Non-Integrating Vector Expressing Human Type III Collagen (COL3) for the Treatment of Superficial Skin Depressions
— · Skin Roughness, Wrinkle, Fine Lines · Active Not Recruiting · est. 2024-10-16
A Study Comparing KB801 Verse Placebo in Patients With Stage 2 or 3 Neurotrophic Keratitis
— · Neurotrophic Keratitis · Recruiting · est. 2026-12
A Study Assessing KB304 for the Treatment of Wrinkles in Women
— · Wrinkles in Decolletage, Pigmentation, Décolleté Wrinkles · Active Not Recruiting · est. 2025-07
A Study Assessing KB707 for the Treatment of Advanced Solid Tumor Malignancies Affecting the Lungs
— · Lung Cancer, Non-small Cell, Lung Cancer Metastatic, Solid Tumor, Adult · Recruiting · est. 2027-02
A Phase I/II Study of KB103, a Topical HSV1-COL7, on DEB Patients
— · Dystrophic Epidermolysis Bullosa · Completed · est. 2019-11-01
A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors
— · Cancer, Melanoma Stage III, Melanoma Stage IV · Recruiting · est. 2027-07
A Study Comparing KB803 and Matched Placebo in Patients With Dystrophic Epidermolysis Bullosa
— · Dystrophic Epidermolysis Bullosa, DEB - Dystrophic Epidermolysis Bullosa, Recessive Dystrophic Epidermolysis Bullosa · Recruiting · est. 2026-12
A Long-term Treatment With B-VEC for Dystrophic Epidermolysis Bullosa
— · Dystrophic Epidermolysis Bullosa, DEB - Dystrophic Epidermolysis Bullosa, Recessive Dystrophic Epidermolysis Bullosa · Completed · est. 2023-07-31
Ph 3 Efficacy and Safety of B-VEC for the Treatment of DEB
— · Dystrophic Epidermolysis Bullosa, Recessive Dystrophic Epidermolysis Bullosa, Dominant Dystrophic Epidermolysis Bullosa · Completed · est. 2021-10-29
No approved products listed under this sponsor in Drugs@FDA (partnered or subsidiary products may be listed elsewhere).
Source: ClinicalTrials.gov (trials where Krystal Biotech is lead sponsor; 14 active or completed) and Drugs@FDA (0 approved products). Registry data can include older or partnered programs; the company's own pipeline page is the official list.
SEC filings — insider trading forms excluded
- 8-K2026-08-03Current report (material event)
- 10-Q2026-08-03Quarterly report
- 8-K2026-07-21Current report (material event)
- 8-K2026-05-20Current report (material event)
- SCHEDULE 13G/A2026-05-04SCHEDULE 13G/A
- 8-K2026-05-04Current report (material event)
- 10-Q2026-05-04Quarterly report
- SCHEDULE 13G2026-04-29SCHEDULE 13G
- ARS2026-04-03Annual report to holders
- DEFA14A2026-04-03DEFA14A
- DEF 14A2026-04-03Proxy statement
- SCHEDULE 13G/A2026-03-27SCHEDULE 13G/A
- 8-K2026-02-17Current report (material event)
- 10-K2026-02-17Annual report
- 8-K2026-01-12Current report (material event)
- 8-K2026-01-08Current report (material event)
- 8-K2025-12-23Current report (material event)
- 8-K2025-11-03Current report (material event)
- 10-Q2025-11-03Quarterly report
- 8-K2025-10-22Current report (material event)
- 8-K2025-08-04Current report (material event)
- 10-Q2025-08-04Quarterly report
- 8-K2025-07-25Current report (material event)
- 8-K2025-07-24Current report (material event)
- 8-K2025-07-09Current report (material event)
- 8-K2025-06-02Current report (material event)
- 8-K2025-05-19Current report (material event)
- 8-K2025-05-13Current report (material event)
- 8-K2025-05-06Current report (material event)
- 10-Q2025-05-06Quarterly report
- 8-K2025-05-06Current report (material event)
- 8-K2025-04-28Current report (material event)
- ARS2025-04-03Annual report to holders
- DEFA14A2025-04-03DEFA14A
- DEF 14A2025-04-03Proxy statement
- 8-K2025-02-28Current report (material event)
- 8-K2025-02-19Current report (material event)
- 10-K2025-02-19Annual report
- SCHEDULE 13G2025-02-05SCHEDULE 13G
- 8-K2024-12-18Current report (material event)
Source: SEC EDGAR. Forms 3/4/5 and 144 (insider transactions) are intentionally left out.